MRI Biomarkers in ALS
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02405182|
Recruitment Status : Recruiting
First Posted : April 1, 2015
Last Update Posted : May 14, 2018
Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk factor for developing ALS; thus, the societal impact of this devastating disease will become more profound as the population ages. A significant hurdle to finding effective treatment has been an inability to accurately measure brain degeneration in humans. Advanced magnetic resonance imaging (MRI) techniques hold promise in this respect, and may assist in aiding diagnosis and the efficient testing of new drugs.
Different MRI features of brain degeneration will be measured in a large sample of patients with ALS. The study will operate within the Canadian ALS Neuroimaging Consortium (CALSNIC). CALSNIC is a clinical research platform comprised of ALS clinics with standardized clinical and neuroimaging protocols.
|Condition or disease||Intervention/treatment|
|Amyotrophic Lateral Sclerosis ALS Motor Neuron Diseases||Other: Magnetic Resonance Imaging|
This study will use advanced Magnetic Resonance Imaging (MRI) techniques to measure brain changes in ALS and related neurological conditions. Results from cognitive and neurological tests will be compared to the MRI. It is believed that these techniques will reveal changes in the brain that will help us understand normal brain function and the symptoms of neurological diseases as seen in ALS, as well to provide an objective measurement of degeneration (which is called a biomarker). This could improve not only the process by which new drugs for the treatment of neurological diseases are evaluated, but also how health care professionals address the needs of patients with these diseases.
Furthermore, a biomarker may give insight into the biological factors related to the diverse and variable clinical features amongst different patients.
Subjects will be recruited from ALS clinics that are a part of the Canadian ALS Neuroimaging Consortium (CALSNIC). Patients will have a diagnosis of ALS, PLS, PMA, or FTD. Healthy controls will be age and gender matched to patients. Subjects will visit their respective sites to undergo a clinical evaluation and an MRI. Follow up visits will occur at approximately 3-6 month intervals. Most subjects will have 2 follow up visits; more visits may occur for subjects who are physically able to continue in the protocol.
|Study Type :||Observational|
|Estimated Enrollment :||195 participants|
|Official Title:||Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis|
|Actual Study Start Date :||September 2014|
|Estimated Primary Completion Date :||March 2019|
|Estimated Study Completion Date :||January 2020|
ALS patients (as well as patients with other motor neuron diseases such PLS and PMA) will be recruited from ALS clinics under the direction of ALS neurologists who are participating in this study. ALS patients should meet research criteria for possible, probable, probable laboratory-supported, or definite ALS. Patients with a history of CNS disease (e.g. stroke, head injury) or significant psychiatric disease will be ineligible. Patients must be able to undergo a brain MRI for approximately an hour.
Other: Magnetic Resonance Imaging
Other Name: MRI
Healthy controls who are age and gender matched to patients will be recruited. Controls with a history of CNS disease (e.g. stroke, head injury) or significant psychiatric disease will be ineligible. Controls must be able to undergo a brain MRI for approximately an hour.
Other: Magnetic Resonance Imaging
Other Name: MRI
- Change in neuronal and white matter integrity measures. [ Time Frame: 24 months ]The primary analysis will evaluate changes in the brain using various advanced MRI techniques at baseline and specified follow up periods. Patients and controls scans will be compared.
- Correlation of neuronal and white matter integrity measures with clinical indices. [ Time Frame: 30 months ]Secondary analyses will involve MRI comparison to clinical measures both at the time of the baseline scan and over time.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02405182
|Contact: Dennell M Mah, BAfirstname.lastname@example.org|
|University of Calgary / Heritage Medical Research Clinic||Active, not recruiting|
|Calgary, Alberta, Canada, T2N 4Z6|
|University of Alberta||Active, not recruiting|
|Edmonton, Alberta, Canada, T6G 2B7|
|Canada, British Columbia|
|University of British Columbia / GF Strong Rehab Centre||Recruiting|
|Vancouver, British Columbia, Canada, V5Z 2G9|
|Contact: Marife Fabros, RN 604-737-6319 email@example.com|
|Western University / London Health Sciences Centre||Completed|
|London, Ontario, Canada, N6A 5A5|
|University of Toronto / Sunnybrook Health Sciences Centre||Active, not recruiting|
|Toronto, Ontario, Canada, M4N 3M5|
|McGill University / Montreal Neurological Institute and Hospital||Completed|
|Montreal, Quebec, Canada, H3A 2B4|
|Principal Investigator:||Sanjay Kalra, MD, FRCPC||University of Alberta|